PPAR Research

PPAR Research / 2019 / Article

Research Article | Open Access

Volume 2019 |Article ID 2630232 | 9 pages | https://doi.org/10.1155/2019/2630232

Effects of Dual Peroxisome Proliferator-Activated Receptors and Activation in Two Rat Models of Neuropathic Pain

Academic Editor: Stéphane Mandard
Received24 Jan 2019
Revised02 Apr 2019
Accepted10 Apr 2019
Published17 Apr 2019


Neuropathic pain is a growing healthcare problem causing a global burden. Currently used analgesics such as opioids are associated with adverse effects; urging the need for safer alternatives. Here we aimed to investigate the potential analgesic effects of tesaglitazar; dual peroxisome proliferator-activated receptors α and γ (PPARα and γ) agonist in rat models of neuropathic pain. This study also aimed to investigate the modulation of the transient receptor potential vanilloid 1 (TRPV1) receptor activity by tesaglitazar which could provide a potential mechanism that underlie tesaglitazar antinociceptive effects. Von Frey filaments were used to determine the paw withdrawal threshold (PWT) in adult male Sprague Dawley rats (180-250g) following i.p. injection of streptozotocin (STZ) or cisplatin, which were used as models of neuropathic pain. Antinociceptive effects of tesaglitazar were determined 6 hours after drug administration. Cobalt influx assays in cultured dorsal root ganglia (DRG) neurons were used to study the effects of tesaglitazar preincubation on capsaicin-evoked cobalt influx. Both cisplatin and STZ produced a significant decrease in PWT. The higher dose of tesaglitazar (20μg/kg) significantly restored PWT in both neuropathic pain models (P<0.05). 10μM capsaicin produced a robust cobalt response in DRG neurons. Preincubation of DRG neurones with tesaglitazar 6 hours prior to stimulation with capsaicin significantly reduce capsaicin-evoked cobalt responses in a PPARα and PPARγ dependent fashion (P<0.05). In conclusion, tesaglitazar produced significant analgesic effects in STZ and cisplatin-induced neuropathy, possibly by modulating TRPV1 receptor activity. This may be of potential benefit in clinical practice dealing with peripheral neuropathy.

1. Introduction

Peripheral neuropathic pain is a significant pharmaceutical and medical problem. It is usually an undertreated secondary symptom of many diseases including diabetes mellitus and an adverse effect of many chemotherapeutic agents such as cisplatin [1]. Peripheral neuropathic pain is one complication of diabetes and a main dose-limiting adverse effect for cancer patients on many chemotherapeutic agents [2]. It may result from toxic insults, disease states, or nerve injury [3]. Several pharmacological families have been investigated for peripheral neuropathic pain conditions including steroids, opiates, selective serotonin reuptake inhibitor (SSRI), cannabinoids, and the tricyclic antidepressant. Often, those pharmaceutical therapies are not effective or safe and merely supportive [4]. Hence, there is an urgent need to identify new effective and safe therapeutic agents for the treatment of peripheral neuropathic pain.

Animal models of peripheral neuropathic pain have been utilized in preclinical studies to characterize complex mechanisms that underlie and maintain the peripheral neuropathic pain. Of those currently used models are diabetes-induced peripheral neuropathy and chemotherapeutics (in particular Cisplatin)-induced peripheral neuropathy. Those two models could be used to investigate different mechanisms of peripheral neuropathy after an injury to develop novel drugs to alleviate or treat the peripheral neuropathy. Diabetic peripheral neuropathy has been suggested to be a putative consequence of chronic hyperglycemia, dyslipidemia, inflammation, and oxidative stress [5]. Cisplatin-induced peripheral neuropathy is a prevalent type of oncology pain and has traditionally been thought to be a consequence of oxidative stress to the mitochondria that leads to apoptosis [6].

Studies in the last decade suggest that activating the Peroxisome proliferator-activated receptors (PPARs) can alleviate peripheral neuropathic pain, perhaps by their anti-inflammatory effects [7]. PPARs are a family of transcription factors that consists of three isoforms including PPARα, PPARβ/δ (most commonly identified as PPARδ), and PPARγ, which have various tissue expression distributions including pain neuroaxis and distinct physiological roles including inflammation [8]. The commonly prescribed PPAR receptors agonists are the glitazone which has a high affinity for PPARγ [9] and the fibrates which have a high affinity for PPARα [10]. Several glitazones and fibrates have been evaluated separately for their ability to reduce peripheral neuropathic pain [11, 12]. Those studies highlighted the promise of PPARα and PPARγ agonists to alleviate peripheral neuropathic pain. However, a limited number of studies investigated the usefulness of PPARα/PPARγ dual agonists for ameliorating the peripheral neuropathic pain. In this context, PPARα/PPARγ receptors are attractive targets as they are expressed throughout the pain neuroaxis [13]. Targeting both PPARα and PPARγ isoforms could improve the efficacy and provide a superior drug for peripheral neuropathic pain treatment. Tesaglitazar is a dual PPARα/γ agonist [14], previously investigated clinically for its ability to treat type 2 diabetes mellitus [15, 16]. Additionally, it was previously shown to reverse CFA-induced mechanical allodynia in rats significantly [17]. However, the potential value of tesaglitazar in alleviating neuropathic pain and the mechanisms that underlie these antinociceptive effects of it, if any, are poorly understood. Transient receptor potential vanilloid 1 (TRPV1) is a key receptor involved in the development of chronic pain conditions. It was shown to underlie pain hypersensitivity in neuropathic pain [18]. Modulating TRPV1 channel activity was proposed to explain the antinociceptive effects of Palmitoylethanolamine (PEA), a PPARα agonist [1921]. The involvement of both TRPV1 and PPARγ receptors in mediating PEA antinociceptive effect was also reported [22]. These studies indicated a functional and biochemical crosstalk between PPAR receptors and TRPV1 channels. On these bases this study aimed to investigate the therapeutic potential of tesaglitazar in two models of neuropathic pain, Cisplatin-induced peripheral neuropathy and diabetes-induced peripheral neuropathy, and to explore if these effects are dependent on the long-term changes that occur by reducing blood glucose levels. Further aim has been to explore the mechanisms that underlie this action, focusing the attention on the possible interaction with TRPV1 receptor.

2. Materials and Methods

2.1. Animals

Adult male Sprague Dawley rats (180-250g, Jordan University of Science and Technology laboratories) were used for behavioral experiments. Rats were group housed in the Animal House Unit (The University of Jordan), and free accessibility of food and water was insured throughout all experiments. All procedures were done during the animals’ light cycle. Experiments were carried out in accordance with the Animal (Scientific Procedures) Act 1986, International Association for the Study of Pain guidelines and the Scientific Research Committee at the University of Jordan.

2.2. Induction of Diabetic Neuropathy Pain Model

In order to induce diabetes, animals received intraperitoneal (i.p.) injections of STZ (35 mg/kg, Tocris Bioscience, UK) or vehicle (0.1M citrate buffer pH 4.6) under general anesthesia with isoflurane inhalation. Body weight, blood glucose levels, and mechanical allodynia were measured before the injections and weekly after that. Diabetes was confirmed by assaying the glucose levels in blood obtained from the tail vein using Accu-Check Performa (Roche, Germany). Rats with glucose levels greater than 200 mg/dl 3 days after STZ injection were considered diabetic.

2.3. Induction of Chemotherapy-Induced Neuropathy

Rats were treated with daily intraperitoneal (i.p.) injection of 2.3 mg/kg cisplatin (Sigma-Aldrich) or vehicle (0.9% saline) for 5 days, followed by 5 days of rest, for two cycles. Total cumulative doses of 23 mg/kg cisplatin over a total of ten injections were used. Mechanical allodynia was measured before the injections and at the end of each treatment cycles at days 11 and 21.

2.4. Assessment of Mechanical Allodynia

The von Frey filament test was used to measure sensitivity to a punctuate pressure stimulus. Rats were placed in a plastic cage with a wire mesh bottom which allowed full access to the paws. Behavioral accommodation was allowed for at least 25min until cage exploration, and major grooming activities ceased. Subsequently, von Frey filaments (2-15g, with logarithmically incremental stiffness; Bioseb, Vitrolles, France) were applied to the mid-plantar aspect of the left hind paw using the “up-down” method to determine the withdrawal threshold; the von Frey hair was presented perpendicular to the plantar surface and held for approximately 6-8sec [23, 24]. Data are expressed as means ± SEM of paw withdrawal threshold (PWT) in grams.

2.5. Pharmacological Treatments

To assess the effects of tesaglitazar on the development of STZ-induced changes in mechanical hind paw withdrawal thresholds. Tesaglitazar (2, 10, or 20μg/kg, Tocris Bioscience, UK) or vehicle (3% tween 20 in saline) was injected i.p. at week 4 after STZ injection, when mechanical allodynia was fully developed. The nociceptive test was performed at 6 hours after tesaglitazar administration. On the other hand, to evaluate the effects of tesaglitazar on the development of chemotherapy-induced neuropathic pain, tesaglitazar (20μg/kg) or vehicle (3% tween 20 in saline) was injected i.p. at the end of the cisplatin treatment cycles. In all behavioral experiments, the observer was blinded to the treatments.

2.6. Isolation and Culture of Dorsal Root Ganglia (DRGs) Neurons

Male Sprague Dawley rats (400 g) were decapitated to extract all the DRGs (cervical, thoracic, lumbar, and sacral). The neurons were incubated in Dulbecco's Modified Eagle Medium-F12 (DMEM-F12) containing 0.25% collagenase/30 min/37°C followed by 7 min incubation with 0.25% trypsin in DMEM-F12 media containing 1% HEPES buffer and penicillin/streptomycin (1:200). The neurons were triturated 50 times with normal Pasteur pipettes then 50 times with thin-flame polished pipettes. The neurons were then centrifuged at 400 g for 20 min followed by resuspension of the pellet in media containing 10% heat inactivated fetal bovine serum (FBS). After that, the neurons were triturated again with the thin-flame polished pipettes (50 times), filtered with a cell strainer, and cultured in 96 well-plates for 24 hr at 37°C, 5% CO2.

2.7. Cobalt Uptake Assay

After 24 hours, the neurons were treated with different concentrations of capsaicin (100 nm, 1 μM or 10 μM) in 5 mM cobalt chloride for 2 min to choose the concentration of capsaicin for the subsequent experiments. In the control group, only cobalt chloride was added. The cells were then lysed with lysis buffer (20 mM Tris, 150 mM NaCl, and 1% tween 80) without chelating agents. After that, 2-mercaptoethanol (5%) was added to each well, mixed and incubated for few minutes. The color complex was detected by spectrophotometer at 475 nm absorbance. Other wells received capsazepine (10 μM) for 4 minutes prior to 10 μM capsaicin (the chosen concentration in the experiment) to confirm that capsaicin-evoked cobalt influx is TRPV1 mediated. 2 μM tesaglitazar plus 10 μM GW 6471, a selective PPARα antagonist, or 2 μM tesaglitazar plus 10 μM GW 9662, a selective PPARγ antagonist, was applied 6 hours before capsaicin (10 μM) application to assess the effects of tesaglitazar on capsaicin-evoked cobalt influx in DRGs and evaluate the role of PPARα and γ (respectively) in mediating theses effects.

2.8. Data Analysis

Mechanical allodynia data are presented as means ± SEM of PWT in grams. Blood glucose levels are presented as means ± SEM in mg/dL units. Body weight data are presented as means ± SEM in grams. Two-way ANOVA analysis of variance used with time and treatment are the main factors. Significant ANOVA (p≤0.05) was followed by Holm-Sidak post hoc test. Also, Student's t-test or one-way ANOVA test followed by Dunnett’s post hoc was used as appropriate. For cobalt uptake assay, data were presented as percentage of cobalt absorbance in treated wells compared to vehicle-treated wells and presented as means ± SEM of % cobalt influx. Statistical analysis used one-way ANOVA test followed by Dunnett’s post hoc or Tukey’s post hoc as appropriate. All tests were performed using Graph Pad statistical program (Prism 6, San Diego, CA, USA).

3. Results

3.1. Effects of Tesaglitazar on Diabetic Neuropathy Pain

After STZ treatment, blood glucose levels were significantly elevated by the first week and remained elevated for the course of the study compared to vehicle-injected rats (Figure 1(a)). As the disease progressed, the body weights of control animals increased, whereas the body weights of STZ-treated animals decreased steadily (Figure 1(b)). Alongside these changes in weight and blood glucose levels, hind paw mechanical withdrawal thresholds were significantly lowered in the STZ-treated rats compared to the vehicle-treated rats (Figure 1(c)), which is indicating the development of overt pain behavior.

At week 4 after STZ injection, when PWT was significantly reduced, tesaglitazar (2, 10, or 20μg/kg) was injected i.p. and antinociceptive properties of tesaglitazar were evaluated 6 hours after drug administration. The higher two doses of tesaglitazar (10 and 20μg/kg) significantly restored PWT (Figure 2(a)). Notably, none of the tesaglitazar doses used in this study has a significant effect on blood glucose levels 6 hours after drug administration (Figure 2(b)).

3.2. Effects of Tesaglitazar on Chemotherapy-Induced Neuropathy Pain

The findings obtained from this study are suggesting that tesaglitazar's antinociceptive effects are independent of the slower and longer-term cellular and molecular changes that are brought into play by reducing blood glucose levels. To confirm this hypothesis, we evaluated the antinociceptive effects of tesaglitazar on a different model of neuropathic pain (Cisplatin-induced neuropathy pain). After the first treatment cycle, cisplatin-treated rats had no significant reduction in the PWT compared to vehicle-treated controls. However, after the second treatment cycle, cisplatin-treated rats had a significant reduction in the PWT compared to the vehicle-treated group (8.69 ± 0.86 versus 13.49 ± 0.74, P < 0.05, two-way ANOVA, Figure 3(a)), suggesting the development of apparent pain behavior. In order to evaluate the effects of tesaglitazar on the development of chemotherapy-induced neuropathic pain, 20μg/kg tesaglitazar was injected i.p. at the end of the cisplatin treatment cycles (day 21). Tesaglitazar significantly reversed mechanical PWT 6 hours afterdrug administration (Figure 3(b)).

3.3. Effects of Tesaglitazar on Capsaicin-Evoked Cobalt Uptake

Capsaicin produced a concentration-dependent increase in cobalt uptake in cultured DRG cells; only the highest concentration of capsaicin (10 μM) produced a significant effect (Figure 4(a)). Based on that, 10 μM capsaicin is used for the subsequent experiments. Capsazepine (10 μM) significantly blocks capsaicin-evoked cobalt uptake in DRG neurons (8.63 ± 31.68 versus 120.1 ± 7.68, P value < 0.05, Figure 4(b)) confirming the role of TRPV1 receptor in mediating these effects of capsaicin. Similarly, tesaglitazar (2 μM) significantly inhibits capsaicin-evoked cobalt influx in DRG neurons (-25.89 ± 9.95 versus 120.1 ± 7.68, P value < 0.05, Figure 4(b)). Coadministration of the selective PPARα antagonist GW6471 with tesaglitazar significantly reduced the inhibitory effects of tesaglitazar on capsaicin-evoked cobalt influx in DRGs 227.01 ± 102.38 versus -25.89 ± 7.68, P value < 0.05, Figure 4(c)). Similarly, Coadministration of the selective PPARγ antagonist GW9662 with tesaglitazar significantly reduced the inhibitory effects of tesaglitazar on capsaicin-evoked cobalt influx in DRG cells (158.48 ± 42.39 versus -25.89 ± 7.68, P value < 0.05, Figure 4(c)).

4. Discussion

In agreement with previous studies, stable hyperglycemia was observed 3 days after STZ administration in rats. As expected, this diabetogenic action of STZ was accompanied by the development of hyperalgesia in response to mechanical stimulus. This study highlighted the ability of tesaglitazar (10 and 20μg/kg) to relieve pain in STZ-induced neuropathy.

Since tesaglitazar acts as a dual agonist for both PPARα and PPARγ receptors, the involvement of those receptors is likely to mediate its antinociceptive effects. Previous reports revealed that the activation of PPARs decreases the levels of proinflammatory mediators and oxidative stress [25, 26]. Besides, both receptors are expressed in dorsal root ganglia neurons [27, 28], suggesting functional crosstalk. Moreover, the activation of PPARs signaling in both animal and human studies resulted in an improvement of lipid profiles including free fatty acid [29, 30] which is correlated with inflammation in many medical conditions including diabetes [31]. Agonists of the PPARγ and α have been reported to regulate inflammation by modulating the production of inflammatory mediators and adhesion molecules. Recently, it has been shown that tesaglitazar significantly reversed the CFA-induced thermal hyperalgesia [17]; our data also showed that tesaglitazar attenuates the cisplatin-induced tactile allodynia. These findings suggest a possible mechanism of action of antinociceptive effect of tesaglitazar by inhibiting the inflammatory signaling.

Most preclinical studies investigating diabetic neuropathy utilized STZ to induce diabetes in rodents [32, 33]. However, other studies used different animal models of diabetes such as Zucker rats and high-fat diet/STZ rats [34, 35]. Although those models of type 2 diabetes can provide useful information about the progression of nerve dysfunction in diabetes [36], our selection of STZ-induced diabetes model, in which hyperglycemia is a distinctive feature throughout the experiment, was based on the simplicity of experimental procedure and cost [37].

The diabetic rat model used in the present study showed latency to onset of neuropathic pain features (3 weeks) and late resolution/remission of allodynia (6-7 weeks). This latency may be attributed to many factors including, firstly, the chronic effect of STZ such as gradual accumulation of glucose and activation of microglia [38], secondly, time-dependent trafficking of targets such as transports or ion channels that may also have delayed onset with prolonged effects and, lastly, short- and long-term cellular and molecular changes that are induced by elevated blood glucose. Regarding the partial remission/resolution, this might occur due to excessive stimulation activity in those targets contributes to a transient tachyphylaxis, tolerance, or desensitization.

Mechanisms underlying neuropathic pain are still poorly understood. Indeed, the supposed mechanisms depend on the type of model used to induce the neuropathic pain. There are many proposed mechanisms in STZ model that are likely to contribute to the development of neuropathic pain, increase in the activity of neurons, and the central sensitization [39], the nerve fiber density of Schwann cells, axons, and intraepidermal might be affected by STZ treatment [40], spinal microglial activation might be increased [41, 42], and the oxidative stress and mitochondrial dysfunction in diabetic neurons might be induced by high blood glucose [43].

The higher two doses of tesaglitazar (10 and 20ug/kg) were needed to significantly relieve the STZ-induced mechanical allodynia in rats after 4 weeks of the induction. This effect of tesaglitazar probably involves the activation of both PPARα and PPARγ receptors. In contrary to previous reports [44, 45], tesaglitazar in the present study did not alter glucose levels in the STZ-treated rats, probably reflecting the low levels of plasma insulin (compared to control rats) in the STZ model. This hypothesis could limit the extent of any improvement in peripheral insulin sensitivity; the STZ rats are insulin deficient, rather than insulin resistant as the rats were unable to secrete any more insulin.

Since the high glucose level has been reported to contribute to the development of diabetic neuropathy, tesaglitazar-induced relief of diabetic neuropathy can be due to an action upon blood glucose level. However, our findings showed that tesaglitazar did not decrease blood glucose level 6 hours after drug administration. This finding is suggesting that tesaglitazar's antinociceptive effects are independent of the slower and longer-term cellular and molecular changes that are brought into play by reducing blood glucose levels. The exact molecular mechanism underlying such effects is still unknown and deserves further investigations. To further investigate this possibility, we evaluated the antinociceptive effects of tesaglitazar on a different model of neuropathic pain. In agreement with previous studies, we have expectedly shown that cisplatin treatment evokes significant tactile allodynia compared to the vehicle-treated controls, suggesting the development of apparent pain behavior. The higher dose tesaglitazar significantly attenuates the cisplatin-induced tactile allodynia. The mechanisms of cisplatin-induced neuropathy are not fully understood; however, studies demonstrate that it is related to axonal damage of peripheral nerves, causing dysfunctional effects in primary afferent fibers that lead to abnormal impulse transmission, nerve hyperexcitability, and pain [46, 47]. Moreover, several studies report that cisplatin-induced neuropathy is mediated by oxidative stress, apoptosis, and inflammation [48]. The inflammatory alterations play a crucial role, especially nuclear factor kappa B (NF-kB) and tumor necrosis factor alpha (TNF-α) signaling pathways [49]. Ohta et al. found that the cisplatin enhanced NF-κβ phosphorylation significantly through PI3/Akt signaling cascade in ovarian cancer cells [50].

The ability of tesaglitazar to inhibit TRPV1 responses in DRG neurons in a PPARα and PPARγ dependent fashion as revealed by the cobalt influx assays could explain the antinociceptive of tesaglitazar observed in vivo. PPARα ligands such as fenofibrate reduced the expression of cyclooxygenase-2 gene and the production of prostaglandins [51], which in turn are capable of sensitizing TRPV1 channel providing the molecular pathway by which tesaglitazar desensitizes TRPV1 receptor. Anti-inflammatory effects of PPARα have been attributed to the inhibition of the proinflammatory signaling pathways mediated by the transcription-dependent nuclear factor κβ (NF-κβ) and activated protein-1 (AP-1). This signaling pathway is essential to the development of neuropathic pain as described earlier. Furthermore, tesaglitazar can activate PPARα receptors which in turn inhibit the large and the intermediate conductance channels ( and , respectively) [52]. In agreement with our cobalt influx assay findings, Costa and coworkers (2008) have shown that both PPARγ and TRPV1 receptors mediated the antinociceptive effects of PEA in rat model of neuropathic pain [22].

5. Conclusions

This study suggests a new pharmaceutical application of tesaglitazar which exhibits a beneficial property on painful neuropathy characterized by mechanical allodynia and reasoned that tesaglitazar is a potential pharmaceutical agent for treating painful diabetic neuropathy. In the light of the current clinical need for neuropathic pain treatment, this study also provides novel evidence for additional therapeutic potential of PPARα/PPARγ dual activation.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors state no conflicts of interest.


We thank Deanship of Scientific Research in The University of Jordan for funding and Dr. Shatha Albaik for the technical help and the animal welfare.


  1. R. Baron, C. Maier, N. Attal et al., “Peripheral neuropathic pain: a mechanism-related organizing principle based on sensory profiles,” PAIN, vol. 158, pp. 261–272, 2017. View at: Publisher Site | Google Scholar
  2. L. Colloca, T. Ludman, D. Bouhassira et al., “Neuropathic pain,” Nature Reviews Disease Primers, vol. 3, Article ID 17002, 2017. View at: Publisher Site | Google Scholar
  3. A. Areti, V. G. Yerra, V. Naidu, and A. Kumar, “Oxidative stress and nerve damage: Role in chemotherapy induced peripheral neuropathy,” Redox Biology, vol. 2, no. 1, pp. 289–295, 2014. View at: Publisher Site | Google Scholar
  4. C. T. Doughty and R. Seyedsadjadi, “Approach to Peripheral Neuropathy for the Primary Care Clinician,” American Journal of Medicine, vol. 131, no. 9, pp. 1010–1016, 2018. View at: Publisher Site | Google Scholar
  5. S. Tangvarasittichai, “Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus,” World Journal of Diabetes, vol. 6, no. 3, pp. 456–480, 2015. View at: Publisher Site | Google Scholar
  6. J. L. Podratz, A. M. Knight, L. E. Ta et al., “Cisplatin induced Mitochondrial DNA damage in dorsal root ganglion neurons,” Neurobiology of Disease, vol. 41, no. 3, pp. 661–668, 2011. View at: Publisher Site | Google Scholar
  7. J. Morgenweck, O. S. Abdel-aleem, K. C. McNamara, R. R. Donahue, M. Z. Badr, and B. K. Taylor, “Activation of peroxisome proliferator-activated receptor γ in brain inhibits inflammatory pain, dorsal horn expression of Fos, and local edema,” Neuropharmacology, vol. 58, no. 2, pp. 337–345, 2010. View at: Publisher Site | Google Scholar
  8. B. Sung, S. Park, P. Y. Byung, and Y. C. Hae, “Modulation of PPAR in aging, inflammation, and calorie restriction,” The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, vol. 59, no. 10, pp. 997–1006, 2004. View at: Publisher Site | Google Scholar
  9. J. M. Lehmann, L. B. Moore, T. A. Smith-Oliver, W. O. Wilkison, T. M. Willson, and S. A. Kliewer, “An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ),” The Journal of Biological Chemistry, vol. 270, no. 22, pp. 12953–12956, 1995. View at: Publisher Site | Google Scholar
  10. J. Thomas, K. S. Bramlett, C. Montrose et al., “A chemical switch regulates fibrate specificity for peroxisome proliferator-activated receptor α (PPARα) versus liver X receptor,” The Journal of Biological Chemistry, vol. 278, no. 4, pp. 2403–2410, 2003. View at: Publisher Site | Google Scholar
  11. Y. R. Cho, J. H. Lim, M. Y. Kim et al., “Therapeutic effects of fenofibrate on diabetic peripheral neuropathy by improving endothelial and neural survival in db/db mice,” PLoS ONE, vol. 9, Article ID 0083204, 2014. View at: Publisher Site | Google Scholar
  12. R. B. Griggs, R. R. Donahue, B. G. Adkins, K. L. Anderson, O. Thibault, and B. K. Taylor, “Pioglitazone inhibits the development of hyperalgesia and sensitization of spinal nociresponsive neurons in type 2 diabetes,” The Journal of Pain, vol. 17, no. 3, pp. 359–373, 2016. View at: Publisher Site | Google Scholar
  13. O. Braissant, F. Foufelle, C. Scotto, M. Dauça, and W. Wahli, “Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, -β, and -γ in the adult rat,” Endocrinology, vol. 137, no. 1, pp. 354–366, 1996. View at: Publisher Site | Google Scholar
  14. P. Cronet, J. F. Petersen, R. Folmer et al., “Structure of the PPARα and -γ Ligand Binding Domain in Complex with AZ 242; Ligand Selectivity and Agonist Activation in the PPAR Family,” Structure, vol. 9, pp. 699–706, 2001. View at: Publisher Site | Google Scholar
  15. H. Bays, J. McElhattan, and B. S. Bryzinski, “A double-blind, randomised trial of tesaglitazar versus pioglitazone in patients with type 2 diabetes mellitus,” Diabetes and Vascular Disease Research, vol. 4, no. 3, pp. 181–193, 2007. View at: Publisher Site | Google Scholar
  16. R. E. Ratner, S. Parikh, and C. Tou, “Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulin-treated patients with type 2 diabetes,” Diabetes and Vascular Disease Research, vol. 4, no. 3, pp. 214–221, 2007. View at: Publisher Site | Google Scholar
  17. M. Alsalem, A. Altarifi, H. Kalbouneh, H. Al-Zer, B. Azab, and K. El-Salem, “Role of PPARα and PPARγ in mediating the analgesic properties of ibuprofen in vivo and the effects of dual PPARα/γ activation in inflammatory pain model in the rat,” International Journal of Pharmacology, vol. 12, no. 8, pp. 812–820, 2016. View at: Publisher Site | Google Scholar
  18. N. Malek, A. Pajak, N. Kolosowska, M. Kucharczyk, and K. Starowicz, “The importance of TRPV1-sensitisation factors for the development of neuropathic pain,” Molecular and Cellular Neuroscience, vol. 65, pp. 1–10, 2015. View at: Publisher Site | Google Scholar
  19. S. A. Aldossary, M. Alsalem, H. Kalbouneh et al., “The role of transient receptor potential vanilloid receptor 1 and peroxisome proliferator-activated receptors-α in mediating the antinociceptive effects of palmitoylethanolamine in rats,” NeuroReport, 2018. View at: Publisher Site | Google Scholar
  20. P. Ambrosino, M. V. Soldovieri, M. De Maria, C. Russo, and M. Taglialatela, “Functional and biochemical interaction between PPARα receptors and TRPV1 channels: Potential role in PPARα agonists-mediated analgesia,” Pharmacological Research, vol. 87, pp. 113–122, 2014. View at: Publisher Site | Google Scholar
  21. P. Ambrosino, M. V. Soldovieri, C. Russo, and M. Taglialatela, “Activation and desensitization of trpv1 channels in sensory neurons by the peroxisome proliferator-activated receptor α agonist palmitoylethanolamide,” British Journal of Pharmacology, vol. 168, pp. 1430–1444, 2013. View at: Publisher Site | Google Scholar
  22. B. Costa, F. Comelli, I. Bettoni, M. Colleoni, and G. Giagnoni, “The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors,” PAIN, vol. 139, pp. 541–550, 2008. View at: Publisher Site | Google Scholar
  23. S. R. Chaplan, F. W. Bach, J. W. Pogrel, J. M. Chung, and T. L. Yaksh, “Quantitative assessment of tactile allodynia in the rat paw,” Journal of Neuroscience Methods, vol. 53, no. 1, pp. 55–63, 1994. View at: Publisher Site | Google Scholar
  24. M. Alsalem, P. Millns, A. Altarifi, K. El-Salem, V. Chapman, and D. A. Kendall, “Anti-nociceptive and desensitizing effects of olvanil on capsaicin-induced thermal hyperalgesia in the rat,” BMC Pharmacology & Toxicology, vol. 17, p. 31, 2016. View at: Google Scholar
  25. S. Giannini, M. Serio, and A. Galli, “Pleiotropic effects of thiazolidinediones: Taking a look beyond antidiabetic activity,” Journal of Endocrinological Investigation, vol. 27, no. 10, pp. 982–991, 2004. View at: Publisher Site | Google Scholar
  26. Y. Takahashi, M. Hasegawa-Moriyama, T. Sakurai, and E. Inada, “The macrophage-mediated effects of the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone attenuate tactile allodynia in the early phase of neuropathic pain development,” Anesthesia & Analgesia, vol. 113, no. 2, pp. 398–404, 2011. View at: Publisher Site | Google Scholar
  27. J. Wu, J.-J. Wang, T.-T. Liu et al., “PPAR-α acutely inhibits functional activity of ASICs in rat dorsal root ganglion neurons,” Oncotarget , vol. 8, no. 54, pp. 93051–93062, 2017. View at: Google Scholar
  28. T. N. Dunn, T. Akiyama, H. W. Lee et al., “Evaluation of the Synuclein-γ (SNCG) Gene as a PPARγ Target in Murine Adipocytes, Dorsal Root Ganglia Somatosensory Neurons, and Human Adipose Tissue,” PLoS ONE, vol. 10, p. e0115830, 2015. View at: Publisher Site | Google Scholar
  29. T. Varga, Z. Czimmerer, and L. Nagy, “PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation,” Biochimica et Biophysica Acta, vol. 1812, no. 8, pp. 1007–1022, 2011. View at: Publisher Site | Google Scholar
  30. M. Fischer, M. You, M. Matsumoto, and D. W. Crabb, “Peroxisome proliferator-activated receptor α (PPARα) agonist treatment reverses PPARα dysfunction and abnormalities in hepatic lipid metabolism in ethanol-fed mice,” The Journal of Biological Chemistry, vol. 278, no. 30, pp. 27997–28004, 2003. View at: Publisher Site | Google Scholar
  31. C. M. O. Volpe and J. A. Nogueira-Machado, “The dual role of free fatty acid signaling in inflammation and therapeutics,” Recent Patents on Endocrine Metabolic & Immune Drug Discovery, vol. 7, no. 3, pp. 189–197, 2013. View at: Publisher Site | Google Scholar
  32. M. Dobretsov, S. L. Hastings, D. Romanovsky, J. R. Stimers, and J.-M. Zhang, “Mechanical hyperalgesia in rat models of systemic and local hyperglycemia,” Brain Research, vol. 960, no. 1-2, pp. 174–183, 2003. View at: Publisher Site | Google Scholar
  33. D. Romanovsky, S. L. Hastings, J. R. Stimers, and M. Dobretsov, “Relevance of hyperglycemia to early mechanical hyperalgesia in streptozotocin-induced diabetes,” Journal of the Peripheral Nervous System, vol. 9, no. 2, pp. 62–69, 2004. View at: Publisher Site | Google Scholar
  34. F. M. Byrne, S. Cheetham, S. Vickers, and V. Chapman, “Characterisation of pain responses in the high fat diet/streptozotocin model of diabetes and the analgesic effects of antidiabetic treatments,” Journal of Diabetes Research, vol. 2015, Article ID 752481, 13 pages, 2015. View at: Google Scholar
  35. E. P. Davidson, L. J. Coppey, A. Holmes et al., “Characterization of diabetic neuropathy in the Zucker diabetic Sprague-Dawley rat: a new animal model for type 2 diabetes,” Journal of Diabetes Research, vol. 2014, Article ID 714273, 7 pages, 2014. View at: Google Scholar
  36. A. S. Shaikh and R. S. Somani, “Animal models and biomarkers of neuropathy in diabetic rodents,” Indian Journal of Pharmacology, vol. 42, no. 3, pp. 129–134, 2010. View at: Publisher Site | Google Scholar
  37. A. Ulugol, H. C. Karadag, Y. Ipci, M. Tamer, and I. Dokmeci, “The effect of WIN 55,212-2, a cannabinoid agonist, on tactile allodynia in diabetic rats,” Neuroscience Letters, vol. 371, no. 2-3, pp. 167–170, 2004. View at: Publisher Site | Google Scholar
  38. M. A. Churchward, D. R. Tchir, and K. G. Todd, “Microglial Function during Glucose Deprivation: Inflammatory and Neuropsychiatric Implications,” Molecular Neurobiology, vol. 55, no. 2, pp. 1477–1487, 2018. View at: Publisher Site | Google Scholar
  39. A. M. Tan, O. A. Samad, T. Z. Fischer, P. Zhao, A.-K. Persson, and S. G. Waxman, “Maladaptive dendritic spine remodeling contributes to diabetic neuropathic pain,” The Journal of Neuroscience, vol. 32, no. 20, pp. 6795–6807, 2012. View at: Publisher Site | Google Scholar
  40. I. Dey, N. Midha, G. Singh et al., “Diabetic Schwann cells suffer from nerve growth factor and neurotrophin-3 underproduction and poor associability with axons,” Glia, vol. 61, no. 12, pp. 1990–1999, 2013. View at: Publisher Site | Google Scholar
  41. L. Daulhac, C. Mallet, C. Courteix et al., “Diabetes-induced mechanical hyperalgesia involves spinal mitogen-activated protein kinase activation in neurons and microglia via N-methyl-D-aspartate-dependent mechanisms,” Molecular Pharmacology, vol. 70, no. 4, pp. 1246–1254, 2006. View at: Publisher Site | Google Scholar
  42. M. Tsuda, H. Ueno, A. Kataoka, H. Tozaki-Saitoh, and K. Inoue, “Activation of dorsal horn microglia contributes to diabetes-induced tactile allodynia via extracellular signal-regulated protein kinase signaling,” Glia, vol. 56, no. 4, pp. 378–386, 2008. View at: Publisher Site | Google Scholar
  43. M. A. Babizhayev, I. A. Strokov, and V. V. Nosikov, “The role of oxidative stress in diabetic neuropathy: generation of free radical species in the glycation reaction and gene polymorphisms encoding antioxidant enzymes to genetic susceptibility to diabetic neuropathy in population of type I diabetic patients,” Cell Biochemistry and Biophysics, vol. 71, no. 3, pp. 1425–1443, 2015. View at: Publisher Site | Google Scholar
  44. K. Wallenius, A. Kjellstedt, P. Thalén, L. Löfgren, and N. D. Oakes, “The PPARα/γ Agonist, Tesaglitazar, Improves Insulin Mediated Switching of Tissue Glucose and Free Fatty Acid Utilization In Vivo in the Obese Zucker Rat,” PPAR Research, vol. 2013, Article ID 305347, 14 pages, 2013. View at: Google Scholar
  45. B. J. Goldstein, J. Rosenstock, D. Anzalone, C. Tou, and K. Peter Öhman, “Effect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial,” Current Medical Research and Opinion, vol. 22, no. 12, pp. 2575–2590, 2006. View at: Publisher Site | Google Scholar
  46. W. H. Xiao and G. J. Bennett, “Chemotherapy-evoked neuropathic pain: Abnormal spontaneous discharge in A-fiber and C-fiber primary afferent neurons and its suppression by acetyl-l-carnitine,” PAIN, vol. 135, no. 3, pp. 262–270, 2008. View at: Publisher Site | Google Scholar
  47. S. B. Park, A. V. Krishnan, C. S.-Y. Lin, D. Goldstein, M. Friedlander, and M. C. Kiernan, “Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies,” Current Medicinal Chemistry, vol. 15, no. 29, pp. 3081–3094, 2008. View at: Publisher Site | Google Scholar
  48. E. Sakallı Çetin, M. Nazıroğlu, B. Çiğ, İ. S. Övey, and P. Aslan Koşar, “Selenium potentiates the anticancer effect of cisplatin against oxidative stress and calcium ion signaling-induced intracellular toxicity in MCF-7 breast cancer cells: involvement of the TRPV1 channel,” Journal of Receptors and Signal Transduction Research, vol. 37, no. 1, pp. 84–93, 2017. View at: Publisher Site | Google Scholar
  49. C. M. Annunziata, H. T. Stavnes, L. Kleinberg et al., “Nuclear factor κB transcription factors are coexpressed and convey a poor outcome in ovarian cancer,” Cancer, vol. 116, no. 13, pp. 3276–3284, 2010. View at: Publisher Site | Google Scholar
  50. T. Ohta, M. Ohmichi, T. Hayasaka et al., “Inhibition of phosphatidylinositol 3-kinase increases efficacy of cisplatin in in Vivo ovarian cancer models,” Endocrinology, vol. 147, no. 4, pp. 1761–1769, 2006. View at: Publisher Site | Google Scholar
  51. B. Staels, W. Koenig, A. Habib et al., “Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators,” Nature, vol. 393, no. 6687, pp. 790–793, 1998. View at: Publisher Site | Google Scholar
  52. J. LoVerme, R. Russo, G. La Rana et al., “Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha,” The Journal of Pharmacology and Experimental Therapeutics, vol. 319, no. 3, pp. 1051–1061, 2006. View at: Publisher Site | Google Scholar

Copyright © 2019 Mohammad Alsalem et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

1646 Views | 401 Downloads | 2 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.